Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,576.26
(
-0.73%
)
US TECH 100
23,620.80
(
-0.74%
)
Dow Jones
45,808.84
(
-0.90%
)
Brent Oil
107.84
(
1.18%
)
Bitcoin
68,900.00
(
-3.29%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 211289

Monday, 05/15/2017 8:37:48 AM

Monday, May 15, 2017 8:37:48 AM

Post# of 257259
CHRS/MNTA/AMGN/etc—If ABBV's '135 patent is invalidated, it will help all of the companies seeking to commercialize a Humira FoB for the US market—not just CHRS (as the Maxim analyst alleges).

This is a really bad hack job by a sell-side analyst!

ABBV's '135 patent covers biweekly subcutaneous dosing of Humira for RA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today